Securities code: 688617 Securities abbreviation: Huitai Medical Announcement No.: 2025-005

Shenzhen Huitai Medical Equipment Co., Ltd

2024 Annual Results Bulletin Announcement

The Board of Directors and all directors of the Company guarantee that there is no false record or misleading statement in the content of this announcement

or material omissions, and bear legal responsibility for the authenticity, accuracy and completeness of its content in accordance with the law.

The main financial data for 2024 contained in this announcement are preliminary accounting data and have not been audited by an accounting firm

The specific data are based on Shenzhen Huitai Medical Device Co., Ltd. (hereinafter referred to as the "Company") in 2024

The report shall prevail and investors should be reminded to pay attention to the investment risks.

1. Main financial data and indicators for 2024

Unit: RMB

Item Current reporting period Same period last year Change (%)

Total operating income 2,065,801,597.74 1,650,211,802.94 25.18

Operating profit 754,015,156.69 600,414,702.73 25.58

Total profit 746,291,007.81 596,367,791.56 25.14

Net profit attributable to owners of the parent company 673,475,442.45 533,924,244.00 26.14

Deductions attributable to owners of the parent company are not 643,332,101.22 468,349,321.29 37.36

Net profit from recurring gains or losses

Basic earnings per share (RMB) 6.96 5.54 25.63

The weighted average return on equity was 30.40% and 30.19%, an increase of 0.21 percentage points

End of the reporting period Beginning of the reporting period Change of change (%)

Total assets 2,975,722,524.90 2,572,982,295.44 15.65

Owners' equity attributable to parent company 2,511,364,301.51 1,907,142,308.67 31.68

Share capital 97,393,764.00 66,861,357.00 45.67

Net per share attributable to owners of the parent company 25.79 19.70 30.91

Assets (RMB)

Note: 1. Basic earnings per share in the same period last year and net per share attributable to owners of the parent company at the beginning of the reporting period

The assets have been adjusted and presented in accordance with the company's 2023 capital reserve conversion plan to share capital. Other beginnings

This is consistent with the year-end figure of the previous year for statutory disclosure.

2. The above financial data and indicators are filled in with consolidated statement data, but they are unaudited, and the final results are subject to the company's 2024 annual report. If there is a penny difference in the data, it is due to rounding.

2. Explanation of operating performance and financial situation

(1) Description of the operating conditions and financial status of the reporting period and the main factors affecting the operating performance

During the reporting period, the company achieved operating income of 2065.8016 million yuan, an increase of 25.18% over the same period of last year;

net profit attributable to owners of the parent company was 673.4754 million yuan, an increase of 26.14% over the same period of last year; The net profit attributable to the owners of the parent company after deducting non-recurring gains and losses was 643.3321 million yuan, an increase of 37.36% over the same period of last year. At the end of the reporting period, the company's financial position was good, with total assets of 2975.7225 million yuan, an increase of 15.65% over the beginning of the reporting period.

The main reasons affecting the operating performance during the reporting period were: (1) the company continued to deepen market development, continued to carry out various marketing activities, actively gave full play to its business advantages in R&D, technology, quality, market, channels and other aspects, continuously deepened channel linkage, and further improved product coverage and hospital admission rate; (2) Actively expand overseas markets, continue to increase investment in international business, and continuously improve the recognition of products in overseas markets; (3) Continue to consolidate the advantages of medical and engineering integration, always adhere to R&D and innovation, continuously improve product layout through continuous high R&D investment, and continuously strengthen and consolidate R&D strength and product competitiveness in the field of interventional medical devices; (4) The company continues to tap its own potential in "increasing revenue, controlling costs, reducing costs, and improving quality", constantly improves the governance structure, and continuously shows the effect of production automation and scale.

(2) An explanation of the indicators with a change range of more than 30%.

1. The net profit attributable to the owners of the parent company after deducting non-recurring gains and losses increased by 37.36% over the same period of last year, mainly due to the increase in the company's sales scale, the enhancement of product profitability, and the profit growth brought by cost reduction and cost control.

2. The share capital increased by 45.67% compared with the beginning of this reporting period, mainly due to the implementation of the company's 2023 annual rights during the reporting period

Profit distribution, which is caused by the conversion of capital reserve into share capital to all shareholders by 4.5 shares for every 10 shares.

3. The owner's equity attributable to the parent company increased by 31.68% compared with the beginning of the reporting period, and the net assets per share attributable to the owners of the parent company increased by 30.91% compared with the beginning of the reporting period, mainly due to the impact of the company's profit growth.

3. Risk Warning

As of the disclosure date of this announcement, the company has no major uncertainties affecting the accuracy of the content of this performance report. The main financial data of 2024 contained in this announcement are preliminary accounting data, which have not been audited by accounting firms, and the specific data are subject to the audited 2024 annual report officially disclosed by the company.

Board of Directors of Shenzhen Huitai Medical Equipment Co., Ltd

February 25, 2025